Review

Sialorrhea in Patients with Parkinson’s Disease: Safety and Administration of Botulinum Neurotoxin

Gustav Egevad, Valentina Yankova Petkova and Ole Jakob Vilholm
Department of Neurology, Lillebaelt Hospital, Vejle, Denmark

Abstract. Sialorrhea may present as a troublesome symptom in patients suffering from Parkinson’s disease. Current options for treatment include anticholinergic drugs, irradiation, surgery, oral-motor and behavioural therapies, and injection of botulinum neurotoxin (BoNT) in the salivary glands. The aim of this study is to evaluate the safety and administration of BoNT as a treatment for sialorrhea in patients with Parkinson’s disease (PD) based on a review of the studies conducted so far in this field. A PubMed search was conducted using the major keywords sialorrhea, botulinum neurotoxin, botulinum toxin and Parkinson’s disease. The literature search identified 12 articles, which were selected for further analysis. Few adverse effects were described in the studies included in this present review. Various treatment strategies, including different medication dosages, were applied in the studies. BoNT treatment is safe for sialorrhea in patients with PD. Positive effect is well documented, and there have been relatively few reported adverse effects, which have been mild and transient. Based on this review, a treatment algorithm is proposed. Ultrasound guidance may not be necessary when injecting the parotid gland but may improve the effect and safety of administration, especially when injecting the submandibular glands.

Keywords: Parkinson’s disease, sialorrhea, drooling, botulinum neurotoxin, treatment

INTRODUCTION

Parkinson’s disease (PD) is one of the most common degenerative disorders of the central nervous system with an overall incidence of 118 per 100,000 person-years [1]. PD is clinically diagnosed based on motor symptoms: bradykinesia, rigidity, 4–6 Hz rest tremor and postural instability [2]. However, the patient may also suffer from non-motor symptoms such as sialorrhea, which occurs in 32 to 74% of PD patients [3]. Sialorrhea is classified as primary or secondary. Primary sialorrhea occurs when there is excessive production of saliva, while secondary sialorrhea is the result of disorders of the coordinated activity of the orofacial and palatolingual muscles decreasing the clearance of saliva [4]. Research has shown that saliva production is lower in PD patients compared to healthy controls and that sialorrhea is of a secondary nature [5, 6].

In humans, saliva production is primarily mediated by the submandibular, sublingual and parotid glands, which are innervated by the parasympathetic nervous system. When not stimulated, saliva is produced continuously, mainly by the sublingual and submandibular glands [7]. In the stimulated state, the salivary flow increases up to 5-fold, and this increase is mediated by the parotid gland [7]. Sialorrhea has been shown to have a negative effect on social functioning and may lead to aspiration pneumonia and choking [6, 8].
Current options for treatment of sialorrhea in patients suffering from PD include anticholinergic drugs, treatment with botulinum neurotoxin (BoNT), irradiation, surgery and oral-motor and behavioural therapies [9]. Lately, a German guideline for the treatment of sialorrhea has been proposed [10].

BoNT as a possible treatment for sialorrhea was first proposed by Bushara et al. in 1997. These researchers described injection of BoNT into the parotid gland [11]. Intraglandular administration of BoNT inhibits the release of presynaptic acetylcholine at the neurosecretory junctions of the salivary glands [12]. Until now, 7 serotypes of BoNT had been identified (serotypes A-G) [9]. Four different preparations of BoNT have been approved for clinical use: OnabotulinumtoxinA (A/Ona, brand name: BOTOX®), AbobotulinumtoxinA (A/Abo, brand name: Dysport®), IncobotulinumtoxinA (A/Inco, brand name: XEOMIN®) and RimabotulinumtoxinB (B/Rima, brand name: Myobloc®/Neurobloc®).

Since the introduction in 1997, several clinical studies have been conducted on the BoNT treatment of sialorrhea in patients suffering from neurodegenerative diseases like PD and Amyotrophic Lateral Sclerosis (ALS). Recently, a review with a proposal for tailored treatment for BoNT treatment of sialorrhea in ALS has been published [13]. However, a review conducted solely on this treatment modality in PD patients has not yet been conducted. Thus, this review was set up to evaluate the efficacy and safety of the administration of BoNT for the treatment of sialorrhea in patients suffering from PD.

BoNT treatment of sialorrhea has not yet been approved by the FDA, but an approval study is at the moment ongoing.

A PubMed search of English language publications was conducted using the keywords sialorrhea, botulinum toxin, botulinum neurotoxin and Parkinson’s disease. The clinical studies from 2003 to date on BoNT treatment of sialorrhea related to PD were included in the review. The American Academy of Neurology (AAN) Classification of Evidence for Therapeutic Intervention was applied for classification of the individual studies according to level of evidence [14].

DESCRIPTION

Twelve studies fulfilled the inclusion criteria. Of these studies, 7 were conducted on PD patients exclusively [15–21], and 5 included PD patients as well as patients with other diseases [22–26]. The 12 studies are listed in Table 1.

Effect of treatment

The studies reported several methods of evaluation for the effect of BoNT. The drooling score and drooling frequency score (DS-DF), the visual analogue scale (VAS) and cotton-roll weight were the most frequently used methods of evaluation. Overall, the studies reported a positive effect of BoNT on sialorrhea in 50–100% of the patients.

Mancini et al. reported a positive effect in 50% of the patients, with positive effect defined as a 2-point improvement on the drooling scale score [25]. The other studies applied a definition of any improvement in the subjective and/or objective measurements compared to the baseline, Svetel et al. reported a non-responder rate of 32% [22]. Overall, the duration of the effect varied from 1 to 6 months.

Adverse effects

Several adverse effects (AEs) were reported in the studies, including dry mouth, alterations in saliva composition and mild swallowing and chewing difficulties. The AEs were generally reported as mild and transient, and no severe AEs were reported among the PD patients in the studies.

Choice of glands

In 8 studies, BoNT was injected bilaterally into the parotid gland; in 4 studies, injection was performed bilaterally in the parotid and submandibular glands. The number of injection sites in each parotid gland varied from 1 to 2, whereas only 1 site was used for the submandibular glands.

Ultrasound guidance

In 7 studies, the injection sites were located by ultrasound guidance, and anatomical landmarks were used for guidance in the other 5 studies. In the study by Svetel et al. similar response rates to BoNT treatment were observed in the 2 groups of patients with and without ultrasound guidance [15]. However, in the study done by Dogu et al. ultrasound-guided BoNT injections were superior to non-ultrasound-guided injections based on the quantitative saliva measurements [17]. Injection was only performed in the parotid gland in these 2 studies.
Table 1

<table>
<thead>
<tr>
<th>Study</th>
<th>AAN Class</th>
<th>Design</th>
<th>Number of PD patients</th>
<th>Botulinum A or B (serotype)</th>
<th>Total dose</th>
<th>Ultrasound guidance</th>
<th>PG dose</th>
<th>SG dose</th>
<th>Personalised treatment</th>
<th>Duration of effect in months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nobrega et al. 2009 [16]</td>
<td>III P, OL, SC</td>
<td>16</td>
<td>Botulinum A (Dysport®) 250 U</td>
<td>Yes</td>
<td>125 U</td>
<td>–</td>
<td>No</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nobrega et al. 2007 [18]</td>
<td>III P, OL, SC</td>
<td>21</td>
<td>Botulinum A (Dysport®) 250 U</td>
<td>Yes</td>
<td>125 U</td>
<td>–</td>
<td>No</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lagalla et al. 2006 [19]</td>
<td>I, P, R, DB, PC, SC</td>
<td>32</td>
<td>Botulinum A (Botox®) 100 U</td>
<td>No</td>
<td>50 U</td>
<td>–</td>
<td>No</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ono et al. 2007 [20]</td>
<td>I, P, DB, PC, SC</td>
<td>16</td>
<td>Botulinum A (Myobloc®) 2500 U</td>
<td>No</td>
<td>1000 U</td>
<td>2500 U</td>
<td>No</td>
<td>No data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Studies including several diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guidubaldi et al. 2011 [22]</td>
<td>II P, R, CO, DB, SC</td>
<td>7 (N=14)</td>
<td>Botulinum A (Dysport®) 250 U</td>
<td>Yes</td>
<td>100 U</td>
<td>25 U</td>
<td>No</td>
<td>2.5–3</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

P = Prospective; DB = Double-blind; R = Randomized; CO = Cross-over; CS = Comparative study; PC = Placebo-controlled; OL = Open-label; SC = Single-center; MC = Multi-center.
BoNT type-A versus BoNT type-B

One study compared the effects of the two serotypes [19]. In this study, the serotypes had similar effectiveness and safety. However, BoNT type-B demonstrated a shorter latency from the time of injection to onset of effect and a slightly longer duration of the effect.

Dose of BoNT

BoNT type-A was tested in the range of 64–450 U A/Abo and in the range of 25–100 U A/Ona as total dose. BoNT type-B was tested in the range of 1500–3500 U B/Rima. For B/Rima, the best results were seen at the higher dose (3500 U).

CONCLUSION

Effect of treatment

Existing studies on BoNT treatment of sialorrhea in patients with PD differ considerably in methodology. Thus, exact comparison between the studies is difficult, especially when evaluating the effect of BoNT treatment.

Of the studies conducted exclusively on PD patients, 4 were carried out as double-blinded, randomized, placebo-controlled studies [15, 17, 19, 20]. These studies all reported a positive effect of BoNT treatment and provided high-level evidence of the effect of BoNT treatment on sialorrhea in PD patients.

Adverse effects

Only mild, transient adverse effects were seen among the PD patients in the studies included in this review. However, the spread of BoNT to nearby structures has been reported in other studies [27, 28]. Unlike ALS patients, most of the PD patients who develop sialorrhea do not have the assistance of a feeding tube or ventilator. Special precautions must therefore be taken to prevent dysphagia and breathing difficulties when applying BoNT treatment for sialorrhea to PD patients.

Administration

Based on the research, the submandibular and parotid glands should be injected to achieve the best effect in the fasting state [7]. This was also demonstrated in a study on sialorrhea in cerebral palsy [29]. Therefore, it is recommended to inject the submandibular glands when treatment of the parotid gland alone is insufficient. Injection should be done bilaterally.
Ultrasound guidance

All of the studies included in this review applied injection of the parotid gland, and 5 studies did not incorporate ultrasound guidance. Hence, it can be concluded that injection of the parotid gland can be carried out safely without ultrasound injection. Only 4 studies included submandibular gland injection, and 2 of these did not apply ultrasound guidance. Therefore, there is not sufficient evidence supporting the safety and effectiveness of injecting the submandibular glands without the use of ultrasound guidance.

CONCLUDING REMARKS

BoNT treatment is safe for treating sialorrhea in patients with PD. This treatment has a well-documented effect and few adverse effects, which are mild and transient. Based on this review of the literature, an algorithm is proposed to help select the best approach to treatment of the individual patient (Fig. 1). In this algorithm, it is recommended that injection be limited to the parotid gland if ultrasound is not available. Careful information on the possible adverse effects should be given to the patient before initializing the treatment. Ultrasound guidance may not be necessary when injecting the parotid gland alone, but it may improve the safety and effectiveness of the treatment, especially when injecting the submandibular glands.

ACKNOWLEDGMENTS

None.

CONFLICT OF INTERESTS

Gustav Egevad and Valentina Yankova Petkova report no conflict of interests. Ole Jakob Vilholm has participated in studies and/or received grants and funding from the following companies: Allergan, Ipsen and Eisai Inc.

REFERENCES


